The results and conclusions of the work conducted by the Lymphoma Research Experts ecosystem are published in leading medical journals.
Lysa
2020_LYSA_Combining Gene Expression Profiling and Machine Learning to Diagnose B-cell non-Hodgkin Lymphoma
https://www.ncbi.nlm.nih.gov/pubmed/32444689
Lysa
2020_LYSA_Lenalidomide Maintenance for Diffuse Large B-cell Lymphoma Patients Responding to R-CHOP: Quality of Life, Dosing, and Safety Results From the Randomised Controlled REMARC Study
Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300.
Learn more
Lysa
2020_LYSA_High Total Metabolic Tumor Volume at Baseline Predicts Survival Independent of Response to Therapy
Blood 2020 Apr 16;135(16):1396-1405. doi: 10.1182/blood.2019003526
Learn more
Lysa
2020_LYSA_Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project
Haematologica. 2020 Jan;105(1):e33-e36. doi: 10.3324/haematol.2019.223016
Learn more
Lysa
2020_LYSA_REALYSA : une cohorte française multicentrique en vie réelle de patients adultes atteints d’un lymphome
Correspondances en Onco-Hématologie N° 4 / sept. 2020
Learn more
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma
Blood 2018 Jan 11;131(2):174-181
Through the Glass Ceiling.
J Clin Oncol. 2018 Jan 25:JCO2017763961
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.
Cancer Med 2018 Feb 23. doi: 10.1002/cam4.1139
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
ncet Oncol. 2018 Feb 20. pii: S1470-2045(18)30102-5
From genetics to the clinic: a translational perspective on follicular lymphoma
Nat Rev Cancer. 2018 Feb 9. doi: 10.1038/nrc.2017.127
Bendamustine-Based conditioning prior to ASCT: Results of a French Multicenter Study of 474 Patients from LYSA Centers.
Am J Hematol 2018 Feb 23. doi: 10.1002/ajh.25077
Prognostic value of baseline metabolic tumor volume in early stage Hodgkin’s lymphoma in the standard arm of H10 trial.
Blood 2018 Feb 1. pii: blood-2017-07-795476.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2
Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.
Blood 2018 Mar 20. pii: blood-2017-11-816298. doi: 10.1182/blood-2017-11-816298
RNA fusions involving CD28 are rare in peripheral T-Cell lymphomas and concentrate mainly in those derived from follicular helper T cells.
Haematologica 2018 Mar 15. pii: haematol.2017.186767
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
Br J Haematol. 2018 May;181(3):341-349. doi: 10.1111/bjh.15184.
Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?
Eur J Nucl Med Mol Imaging. 2018 Apr 12. doi: 10.1007/s00259-018-4005-4.
Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
J Nucl Med 2018 Apr;59(4):589-595. doi: 10.2967/jnumed.117.193946.
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Blood 2018 Apr 17. pii: blood-2017-11-816405. doi: 10.1182/blood-2017-11-816405.
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
J Clin Oncol. 2018 Apr 19:JCO2017765198. doi: 10.1200/JCO.2017.76.5198
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma
Blood Adv. 2018 Apr 10;2(7):807-816. doi: 10.1182/bloodadvances.2017015164.
How I manage patients with relapsed/refractory diffuse large B cell lymphoma
Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15412.
Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
Haematologica 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554
Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
Blood. 2018 May 2. pii: blood-2018-02-811174. doi: 10.1182/blood-2018-02-811174.